These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 34040611)

  • 1. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
    Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
    Front Immunol; 2021; 12():669496. PubMed ID: 34040611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody.
    Harwardt J; Carrara SC; Bogen JP; Schoenfeld K; Grzeschik J; Hock B; Kolmar H
    Front Immunol; 2023; 14():1170042. PubMed ID: 37081888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expeditious Generation of Biparatopic Common Light Chain Antibodies
    Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
    Front Immunol; 2020; 11():606878. PubMed ID: 33424853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
    Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
    Front Immunol; 2021; 12():801368. PubMed ID: 35087526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
    Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
    Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.
    Ulitzka M; Harwardt J; Lipinski B; Tran H; Hock B; Kolmar H
    Molecules; 2024 Mar; 29(5):. PubMed ID: 38474651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
    Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
    MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
    Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
    Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
    Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization.
    Harwardt J; Bogen JP; Carrara SC; Ulitzka M; Grzeschik J; Hock B; Kolmar H
    Front Immunol; 2022; 13():888838. PubMed ID: 35479092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
    Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
    Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
    Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
    MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies.
    Pfeifer Serrahima J; Schoenfeld K; Kühnel I; Harwardt J; Macarrón Palacios A; Prüfer M; Kolaric M; Oberoi P; Kolmar H; Wels WS
    Front Immunol; 2024; 15():1457887. PubMed ID: 39267747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
    Zhao Y; Li Y; Wu X; Li L; Liu J; Wang Y; Liu Y; Li Q; Wang Z
    Cancer Biol Ther; 2020; 21(1):72-80. PubMed ID: 31564196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.